News for EPZM Stock

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 Ipsen to acquire Epizyme, expanding its portfolio in oncology Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting Epizyme To Participate in H.C. Wainwright Global Investment Conference Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update Epizyme Announces Date of First Quarter 2022 Financial Results Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update Epizyme to Participate in Upcoming Healthcare Conferences in March Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results Epizyme Announces Pricing of Public Offering of Common Stock Epizyme Announces Proposed Public Offering of Common Stock Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting Epizyme Announces Updates to Its Board of Directors Epizyme to Participate in Jefferies London Healthcare Conference Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414 Epizyme Announces Date of Third Quarter 2021 Financial Results Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Epizyme Announces CEO Succession Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China Epizyme Announces Date of Second Quarter 2021 Financial Results Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients Epizyme to Participate in Jefferies Virtual Healthcare Conference Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results Epizyme Announces Date of First Quarter 2021 Financial Results Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call Epizyme to Host Strategic Vision Call on March 2, 2021 Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences Epizyme to Participate in Jefferies Virtual London Healthcare Conference Epizyme Reports Business Progress and Third Quarter 2020 Financial Results Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives Epizyme Announces Date of Third Quarter 2020 Financial Results Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma